Clinical Trials Logo

Clinical Trial Summary

This study is a multi center double-blinded randomized controlled superiority trial, comparing the effects on postimplantatrion syndrome of a single preoperative dose of dexamethasone vs. standard treatment in endovascular aneurysm repair. Participating researchers must be vascular surgeons or vascular anesthesiologists certified by national entities. Recruitment is expected to begin in the second semester of 2023. The trial will follow the ICH-GCP guidelines and national and international legislation and reporting will be performed according to CONSORT 2010 guidelines. Site inclusion requires hospital ethics committee approval. Written informed consent is mandatory for all patients and the information and consent forms must be approved by Institutional Ethics Committee.


Clinical Trial Description

Post-Implantation Syndrome (PIS) consists on an inflammatory reaction after endovascular aneurysm repair of abdominal aortic aneurysms (EVAR) whose etiology and pathophysiology is still unclear, but is characterized by flu-like symptoms, with fever and elevation of analytical inflammatory parameters in the postoperative period. It is associated with a length of hospital stay and there are some studies that indicate an association with lower quality of life, increase in cardiovascular complications up to one year later and aneurysm-related complications. PIS is defined by the presence of two criteria: tympanic temperature greater than 38ºC and CRP greater than 75 mg/L in the first three postoperative days. Dexamethasone was the selected glucocorticoid, since it has virtually no action mineralocorticoid, has been tested in the perioperative context and is administered frequently in this context, namely at CHULC. Its use is intended to reduce symptoms associated with orotracheal extubation, pain, nausea and quality of life, without adverse effects relevant associates. Study hypothesis: A single dose of 4mg dose of intravenous dexamethasone administered 30 minutes before surgery reduces the incidence and magnitude of PIS after EVAR. Elegibility criteria: All the patients treated electively for a degenerative infrarenal abdominal aortic aneurysm by implantation of an endograft are eligible for this study. Patients treated for mycotic aneurysms, aortic dissections and inflammatory aneurysms are not eligible for this study, as well as patients with known inflammatory or infectious diseases and/or preoperative anti-inflammatory therapeutic. If additional procedures, as endoanchors, proximal extension with a cuff or iliac branch device, are performed during primary EVAR, the patients should be enrolled. Primary endpoints: The chosen primary endpoint is the occurrence of postimplantation syndrome, which is defined as fever (auricular temperature >38ºC) and elevation of CRP (> 75 mg/L), during the first 3 days after operation. Secondary endpoints Efficacy endpoints are length of hospital stay, cardiovascular events, AAA-related complications and quality of life at 30 days and one year. Safety endpoints relate to potential side effects of dexamethasone, as taste disturbances, hyperglycemia, flushing, rise in blood pressure, palpitations, headache, sleep isturbances,depression,euphoria, bradycardia, and cardiac decompensation in the first 30 days after operation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06044480
Study type Interventional
Source Centro Hospitalar de Lisboa Central
Contact Rita Ferreira, MD
Phone +351213594000
Email rita.sferreira33@gmail.com
Status Not yet recruiting
Phase Phase 4
Start date November 1, 2023
Completion date May 31, 2026

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05549895 - Effect of Intrathecal Dexamethasone on Intra-operative Hemodynamic in Elderly Patients Undergoing Urologic Endoscopic Surgery Phase 4
Recruiting NCT04025840 - Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery Phase 4
Completed NCT03688269 - Minimal Effective Concentration (EC90) of Ropivacaine Phase 3
Recruiting NCT03043495 - Dexamethasone Dose in Low Volume Bupivacaine USG Supraclavicular Block Phase 4
Completed NCT05070468 - Effect of Dexamethasone on Labor Induction Phase 3
Completed NCT03874936 - The Effect of Perioperative Dexamethasone Administration on Postoperative Pain in Patients Undergoing Periacetabular Osteotomy. Phase 2/Phase 3
Recruiting NCT06133712 - Dexmedetomidine, Ozone and Dexamethasone Local Injection in Carpal Tunnel Syndrome for Pain Relief N/A
Recruiting NCT04266977 - Restrictive Use of Dexamethasone in Glioblastoma N/A
Recruiting NCT02112864 - Dexamethasone for Reduction of Post Thoracotomy Pain Syndrome N/A
Not yet recruiting NCT05825378 - The Effect of Intercostal Nerve Block With Dexamethasone and Ropivacaine on Rebound Pain After Thoracoscopic Surgery N/A
Recruiting NCT05731960 - Evaluating the Effect of Intravenous Dexamethasone on the Duration of Spinal Anesthesia After Cesarean Delivery Phase 4
Recruiting NCT04654507 - Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children Phase 3
Completed NCT03125941 - High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Mastectomy Phase 4
Unknown status NCT02178449 - Prolongation of Pain Free Time by the Use of Dexamethasone in Peripheral Nerve Blockade Phase 4
Not yet recruiting NCT04763434 - Dexamethasone and Dexmedetomidine as Adjuvants to Ropivacaine in Ultrasound-guided Multilevel Thoracic Paravertebral Block for Lobectomy: A Prospective, Randomized, Triple-blind Study Phase 4
Completed NCT04767256 - Intravenous Dexamethasone and Dexmedetomidine on the Analgesic Efficacy of Erector Spinae Plane Block N/A
Completed NCT03456752 - Perioperative Dexamethasone on Postoperative Outcome in IBD Phase 2
Withdrawn NCT01277731 - Methylprednisolone Replacement for Dexamethasone-induced Hiccup N/A
Completed NCT06085417 - Comparison of the Effects of Dexamethasone and magnesıum Sulphate Used as Adjuvant in Infraclavicular Nerve Block. N/A
Completed NCT04714112 - Low-dose Intravenous Dexamethasone at Different Times as Adjunvants for Brachial Plexus Blocks Phase 4